ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ODD ODDITY Tech Ltd.

Market Closed 01-16 16:00:00 EST

35.40

+0.06

+0.17%

盘后35.39

-0.01-0.03%

19:55 EST

High35.62	Low34.64	Vol683.79K
Open35.30	D1 Closing35.34	Amplitude2.77%
Mkt Cap2.03B	Tradable Cap1.37B	Total Shares57.44M
T/O24.11M	T/O Rate1.77%	Tradable Shares38.70M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ODD","market":"US","secType":"STK","nameCN":"ODDITY Tech Ltd.","latestPrice":35.4,"timestamp":1768597200000,"preClose":35.34,"halted":0,"volume":683786,"hourTrading":{"tag":"盘后","latestPrice":35.39,"preClose":35.4,"latestTime":"19:55 EST","volume":19552,"amount":692138.47,"timestamp":1768611336257,"change":-0.01,"changeRate":-0.000282,"amplitude":0},"delay":0,"changeRate":0.0016977928692698122,"floatShares":38696732,"shares":57438900,"eps":1.791771,"marketStatus":"Market Closed","change":0.06,"latestTime":"01-16 16:00:00 EST","open":35.3,"high":35.62,"low":34.6401,"amount":24109213.97812,"amplitude":0.027728,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.791771,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"listingDate":1689739200000,"exchange":"NASDAQ","adjPreClose":35.34,"preHourTrading":{"tag":"盘前","latestPrice":35.54,"preClose":35.34,"latestTime":"09:27 EST","volume":774,"amount":27087.41484,"timestamp":1768573670226,"change":0.2,"changeRate":0.005659,"amplitude":0.006508},"postHourTrading":{"tag":"盘后","latestPrice":35.39,"preClose":35.4,"latestTime":"19:55 EST","volume":19552,"amount":692138.47,"timestamp":1768611336257,"change":-0.01,"changeRate":-0.000282,"amplitude":0},"volumeRatio":0.4781903530088486,"impliedVol":0.4643,"impliedVolPercentile":0.008},"requestUrl":"/m/hq/s/ODD/wiki","defaultTab":"wiki","newsList":[{"id":"2604450789","title":"Assessing Oddity Tech (ODD) Valuation After Analyst Praise And METHODIQ Skincare Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2604450789","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604450789?lang=en_us&edition=fundamental","pubTime":"2026-01-17 12:29","pubTimestamp":1768624166,"startTime":"0","endTime":"0","summary":"Oddity Tech (NasdaqGM:ODD) is back in focus after an influential analyst highlighted its recent skincare launch, METHODIQ, along with consistent revenue growth and EBITDA margins near 20%, which has helped lift investor interest in the stock.\nSee our latest analysis for Oddity Tech.\nAt a share price of $35.34, Oddity Tech has seen a 4.56% 1 day share price return, but weaker 30 day and 90 day share price returns of 16.34% and 30.50%, with a 1 year total shareholder return of 19.39%. This...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/assessing-oddity-tech-odd-valuation-after-analyst-praise-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/assessing-oddity-tech-odd-valuation-after-analyst-praise-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4551","IE0009354923.USD","AI","BK4023","BK4587","BK4183","BK4585","BK4543","BK4601","BK4588","ETH","NPL.SI","BK6100","ODD","BK4528"],"gpt_icon":0},{"id":"2603934843","title":"Odd Burger Delays Annual Filings After Financing Default Triggers Liquidity Crunch","url":"https://stock-news.laohu8.com/highlight/detail?id=2603934843","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603934843?lang=en_us&edition=fundamental","pubTime":"2026-01-16 07:38","pubTimestamp":1768520309,"startTime":"0","endTime":"0","summary":"Odd Burger Corporation ( ($TSE:ODD) ) has issued an announcement. Odd Burger Corporation has warned that it will miss the January 28, 2026 deadline...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/odd-burger-delays-annual-filings-after-financing-default-triggers-liquidity-crunch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/odd-burger-delays-annual-filings-after-financing-default-triggers-liquidity-crunch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","ODD","IE0009354923.USD"],"gpt_icon":0},{"id":"2603524582","title":"ODDITY Tech Secures Expanded $350 Million Credit Facilities to Fund Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2603524582","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603524582?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:47","pubTimestamp":1768258077,"startTime":"0","endTime":"0","summary":"The latest update is out from ODDITY Tech Ltd. Class A ( ($ODD) ). On January 12, 2026, ODDITY Tech Ltd. disclosed that it has amended its existing...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oddity-tech-secures-expanded-350-million-credit-facilities-to-fund-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oddity-tech-secures-expanded-350-million-credit-facilities-to-fund-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD","IE0009354923.USD","BK4183"],"gpt_icon":0},{"id":"2603216885","title":"Oddity Tech Ltd: Co Has Entered Into Amendments to Existing Agreements With Syndicate of Banks to Secure Credit Facilities for Total of $350 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2603216885","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603216885?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:21","pubTimestamp":1768256515,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD1S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ODD","IE0009354923.USD","BK4183"],"gpt_icon":0},{"id":"2603252156","title":"Oddity Tech Secures $350 Million Credit Facility to Boost Growth and Flexibility","url":"https://stock-news.laohu8.com/highlight/detail?id=2603252156","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603252156?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:20","pubTimestamp":1768256434,"startTime":"0","endTime":"0","summary":"Oddity Tech Ltd. has secured amendments to its existing credit agreements with a syndicate of banks, increasing its available credit facilities from $200 million to $350 million. The new agreements, effective January 15, 2026, will provide the company with undrawn credit lines available for drawdown over three years, through January 14, 2029. Borrowings will accrue interest at SOFR plus 2.7% for term loans maturing in 2031, and a 0.3% commitment fee will apply to unused amounts. The facilities are intended to enhance Oddity Tech’s financial flexibility for growth initiatives, acquisitions, share buybacks, and general corporate purposes, and are subject to customary covenants, including a net debt-to-EBITDA ratio not exceeding 4x. The agreements are guaranteed by certain company subsidiaries and benefit from a negative pledge.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL7TdQkq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","ODD","BK4183"],"gpt_icon":0},{"id":"2602548878","title":"Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2602548878","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602548878?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222800,"startTime":"0","endTime":"0","summary":"Company to also participate in Fireside Chat at Lytham Partners 2026 Investor Healthcare Summit on Thursday, January 15, 2026SAN FRANCISCO, Jan.  12, 2026  (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, I","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216838/0/en/Cadrenal-Therapeutics-Highlights-High-Incidence-of-Thrombotic-Complications-in-Heparin-Induced-Thrombocytopenia-HIT-at-the-J-P-Morgan-Healthcare-Conference-and-VLX-1005-as-a-Potent.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0912757837.SGD","LU0128526141.USD","ODD","BK4109","BK4504","LU0106831901.USD","LU0029874061.USD","LU0267386448.USD","LU1244550494.USD","BK4581","LU0557290698.USD","LU0320765646.SGD","LENZ","LU1791710400.SGD","LU1732800096.USD","LU2463526074.USD","LU0006306889.USD","LU1791710582.SGD","XBI","LABU","LU1668664300.SGD","LU0234570918.USD","LU1720051017.SGD","LU1989772923.USD","LU1548497426.USD","BK4137","IE00BKVL7J92.USD","BK4139","HIT","LU1162221912.USD","XLV","LU0314104364.USD","BK4539","LU0528227936.USD","LU1989772840.SGD","BK4183","LU2357305700.SGD","LU0795875086.SGD","HCSG","LU0795875169.SGD","LU0882574139.USD","BK4007","LU2133065610.SGD","BK4588","LU2271345857.HKD","ASH","LU1732799900.SGD","LU2089283258.USD","LU2111349929.HKD","LU0225283273.USD"],"gpt_icon":0},{"id":"2601260393","title":"Is It Time To Reassess Oddity Tech (ODD) After Recent Share Price Weakness?","url":"https://stock-news.laohu8.com/highlight/detail?id=2601260393","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601260393?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:40","pubTimestamp":1767883258,"startTime":"0","endTime":"0","summary":"If you are wondering whether Oddity Tech at around US$38 is attractively priced or not, this article walks through what the numbers say about its current valuation.\nThe share price has recently been under pressure, with returns of a 5.4% decline over the last 7 days, an 11.6% decline over 30 days, and a 12.4% decline over the past year. This can change how investors think about both risk and opportunity.\nRecent coverage of Oddity Tech has focused on how the business is positioning itself...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/is-it-time-to-reassess-oddity-tech-odd-after-recent-share-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/is-it-time-to-reassess-oddity-tech-odd-after-recent-share-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4183","IE0009354923.USD","ODD","DCF"],"gpt_icon":0},{"id":"2601988133","title":"ODDITY Tech Is Maintained at Overweight by Keybanc","url":"https://stock-news.laohu8.com/highlight/detail?id=2601988133","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601988133?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:29","pubTimestamp":1767882540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 09:29 ET (14:29 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD"],"gpt_icon":0},{"id":"2601637023","title":"KeyBanc Reaffirms Their Buy Rating on ODDITY Tech Ltd. Class A (ODD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601637023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601637023?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:16","pubTimestamp":1767870990,"startTime":"0","endTime":"0","summary":"In a report released today, Scott Schoenhaus from KeyBanc maintained a Buy rating on ODDITY Tech Ltd. Class A, with a price target of $50.00. Accor...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/keybanc-reaffirms-their-buy-rating-on-oddity-tech-ltd-class-a-odd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/keybanc-reaffirms-their-buy-rating-on-oddity-tech-ltd-class-a-odd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD"],"gpt_icon":0},{"id":"2601389221","title":"Oddity Tech Ltd. Chief Science Officer Departs","url":"https://stock-news.laohu8.com/highlight/detail?id=2601389221","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601389221?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:26","pubTimestamp":1767821203,"startTime":"0","endTime":"0","summary":"Oddity Tech Ltd. announced that Dr. Ido Bachelet is no longer employed with the company. His responsibilities as Chief Science Officer of ODDITY LABS have been taken over by other members of the leadership team. The company stated that this change will not affect its financial outlook or ongoing projects.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oddity Tech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL3h5fcF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","BK4183","IE0009354923.USD"],"gpt_icon":0},{"id":"2591250996","title":"Highlighting December 2025's Growth Leaders With Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2591250996","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591250996?lang=en_us&edition=fundamental","pubTime":"2025-12-16 01:05","pubTimestamp":1765818349,"startTime":"0","endTime":"0","summary":"As the United States stock market grapples with concerns over an AI bubble, technology shares have been under pressure, causing declines in major indices like the Nasdaq and Dow Jones Industrial Average. In such a volatile environment, companies with strong growth potential and high insider ownership can offer investors a sense of stability and alignment of interests between management and shareholders.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eton/eton-pharmaceuticals/news/highlighting-december-2025s-growth-leaders-with-insider-owne","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eton/eton-pharmaceuticals/news/highlighting-december-2025s-growth-leaders-with-insider-owne","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4096","NIU.AU","BK4543","KRMN","STUB","LU0056508442.USD","BK4141","BK4142","IE0009354923.USD","LU0082616367.USD","ODD","LU0605514214.HKD","BK4192","LU1861220033.SGD","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU0231459107.USD","WEST","IE00B894F039.SGD","BK4023","SES","BK4585","BK4608","LU2460026573.USD","NIU","BK4558","ALAB","LU2360106780.USD","LU0650527681.SGD","LU0274383776.USD","LU0594300179.USD","BK4183","IE00BZ9MQY76.HKD","BK4007","LU2087625088.SGD","ETON","BK4555","BK4170","ATAT","BK4187","SMCI","LU0353189763.USD","BK4539","APP","LU2063271972.USD","PROP","CRDO","LU0594300419.USD","BK4213","BK4212"],"gpt_icon":1},{"id":"2591677686","title":"ODDITY Tech Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2591677686","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591677686?lang=en_us&edition=fundamental","pubTime":"2025-12-13 03:18","pubTimestamp":1765567080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 14:18 ET (19:18 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD"],"gpt_icon":0},{"id":"2590516616","title":"Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516616","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516616?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:05","pubTimestamp":1765458300,"startTime":"0","endTime":"0","summary":"Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and onlypotent, highly selective inhibitor of human 12-LOX in clinical testing,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203875/0/en/Cadrenal-Therapeutics-Acquires-VLX-1005-a-First-in-Class-Phase-2-12-LOX-Inhibitor-for-Patients-with-Heparin-Induced-Thrombocytopenia-HIT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","LENZ","BK4539","ODD","BK4173","IE0009354923.USD","HIT","TE","BK4096","BK4007","BK4139"],"gpt_icon":0},{"id":"2590166035","title":"Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590166035","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590166035?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458000,"startTime":"0","endTime":"0","summary":"EMBOLD data to serve as basis of efficacy and safety following discussion with the FDABOSTON, Dec.  11, 2025  (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biop","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203828/0/en/Praxis-Precision-Medicines-Announces-Plans-to-File-an-NDA-for-Relutrigine-in-SCN2A-and-SCN8A-Developmental-and-Epileptic-Encephalopathies-in-Early-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4200","BK4183","IE0009354923.USD","BK4139","PRAX","LU0889565916.HKD","BK4135","LU0320765992.SGD","ODD","LU0109394709.USD","ASO","CNS","BK4561"],"gpt_icon":0},{"id":"2590343065","title":"Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2590343065","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590343065?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:00","pubTimestamp":1765281600,"startTime":"0","endTime":"0","summary":"ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202225/0/en/Senti-Bio-Announces-Updated-SENTI-202-Clinical-Data-from-Ongoing-Phase-1-Trial-in-Relapsed-or-Refractory-Acute-Myeloid-Leukemia-Patients-Demonstrating-Deep-MRD-Negative-Durable-Com.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4585","IE00BYQQ9H92.USD","LD","LU2211817866.USD","LU1721428933.USD","LU0347712357.USD","ODD","IE00BFXG0V08.USD","AEI","LU2413666426.HKD","BK4533","CR","BK4109","BK4161","MTD","ORR","ASH","LU2413666699.HKD","LU2463526074.USD","BK4024","BK4563","BK4567","LU1093756168.USD","BK4183","BK4588","BK4121","LU1093756325.SGD","IE0009354923.USD"],"gpt_icon":0},{"id":"2589018258","title":"Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2589018258","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589018258?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:20","pubTimestamp":1765149600,"startTime":"0","endTime":"0","summary":"LOS ANGELES, CA, Dec.  07, 2025  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201157/0/en/Immix-Biopharma-Announces-Pricing-of-Upsized-100-Million-Underwritten-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","LU0314104364.USD","LU0795875169.SGD","LU0795875086.SGD","BK4588","LU0225283273.USD","LU0557290698.USD","LU0234570918.USD","LU1732800096.USD","LU1074936037.SGD","LU1989772840.SGD","IE0009354923.USD","LU0267386448.USD","LU0528227936.USD","LU1668664300.SGD","BK4581","LU2089283258.USD","LU1791710400.SGD","LU2089284900.SGD","BK4534","LU2357305700.SGD","BK4516","LU0912757837.SGD","LU1244550221.USD","LU0320765646.SGD","LU2347655156.SGD","LU1363072403.SGD","LU1989772923.USD","LU2133065610.SGD","LU1548497426.USD","LU1791710582.SGD","LU0882574139.USD","LU0971096721.USD","LU2111349929.HKD","LU2023251221.USD","ODD","BK4183","IE00BZ1G4Q59.USD","LU1720051017.SGD","LU1244550577.SGD","LU1732799900.SGD","LU0158827948.USD","LU0106261372.USD","LU1162221912.USD","LU1244550494.USD","LU1720051108.HKD","LU0098860793.USD","LU2028103732.USD","LU2271345857.HKD","LU0106831901.USD"],"gpt_icon":0},{"id":"2589801826","title":"At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801826","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589801826?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:15","pubTimestamp":1765149300,"startTime":"0","endTime":"0","summary":"– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee – – In four out of five pending patients, MRD negativity in bone marrow predic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201155/0/en/At-ASH-2025-Oral-Presentation-Immix-Biopharma-Reports-Positive-Phase-2-NXC-201-Results-Advancing-Toward-BLA-Submission-as-a-Potentially-First-and-Best-in-Class-Therapy-for-relapsed.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","AL","BK4022","BK4572","LU1169590202.USD","NXC","BK4161","CAR","BK4183","LU1169589451.USD","IE0034390439.USD","LU2463526074.USD","BK4109","BK4104","KOL","BK4230","ODD","IE00B19Z6F94.USD","CR","IE0009354923.USD"],"gpt_icon":0},{"id":"2588062470","title":"Cboe to Offer Nearly 24-Hour Trading for Russell 2000 Options, Expanding Global Access to U.S. Small-Cap Equities","url":"https://stock-news.laohu8.com/highlight/detail?id=2588062470","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588062470?lang=en_us&edition=fundamental","pubTime":"2025-12-03 07:47","pubTimestamp":1764719220,"startTime":"0","endTime":"0","summary":"Russell 2000 Index  options to trade nearly 24x5 during Cboe's Global Trading Hours. Expansion that may allow European and Asia-Pacific traders to more easily manage U.S. small-cap exposure. Initiative is part of Cboe's ongoing efforts to expand global access to its proprietary U.S. equity index options. CHICAGO, Dec. 3, 2025 /PRNewswire/ -- Cboe Global Markets, Inc. , the world's leading derivatives and securities exchange network, today announced plans to extend trading hours for its Russell 2000 Index  options suite to nearly 24 hours a day, five days a week, beginning February 9, 2026.The Russell 2000 Index measures the performance of U.S. small-cap equities across sectors and has long served as a barometer of small-cap performance. As of the end of November, average daily volume in Cboe's RUT options has grown to nearly 75 thousand contracts, up 66% compared to full year 2022, as more traders look to manage risk and implement daily options strategies. The Russell 2000 Index has","market":"sh","thumbnail":"https://mma.prnewswire.com/media/622233/5652355/Cboe_GM_New_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/622233/5652355/Cboe_GM_New_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/cboe-to-offer-nearly-24-hour-trading-for-russell-2000-options-expanding-global-access-to-us-small-cap-equities-302631100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7043","IE0009354923.USD","BK7024","SPX.AU","BK4139","GTH","GTH.AU","ODD","BK4183"],"gpt_icon":0},{"id":"2586420654","title":"Unicycive Therapeutics to Participate in Upcoming Investor Events in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2586420654","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586420654?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:05","pubTimestamp":1764072300,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., Nov.  25, 2025  (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Co","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194215/0/en/Unicycive-Therapeutics-to-Participate-in-Upcoming-Investor-Events-in-December.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","BK4539","IE0009354923.USD","BK4183","BK4139","UNCY"],"gpt_icon":0},{"id":"2585144756","title":"Oddity Tech's Methodiq Telehealth Platform to be Key Driver for Stock Going Ahead, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2585144756","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585144756?lang=en_us&edition=fundamental","pubTime":"2025-11-21 23:53","pubTimestamp":1763740393,"startTime":"0","endTime":"0","summary":"Oddity Tech's  potential success of the Methodiq app-based telehealth platform will be a key driver for the stock going ahead, Morgan Stanley analysts said in a Friday note.Analysts said that while a challenging consumer environment has pressured beauty stocks and fears loom around a recent slowdown in Oddity Tech's US credit card data, the company posted \"solid\" Q3 upside and that its near-term delivery remains \"impressive\".Oddity Tech reported Q3 adjusted earnings late Wednesday of $0.40 per diluted share, beating a FactSet analyst poll of $0.36. Revenue in the three months ended Sept. 30 was $147.9 million compared with a FactSet survey of $145.5 million.Morgan Stanley lowered the stock's rating to $49 from $61 to reflect a more uncertain US environment. It retained an equalweight rating.Price: 38.60, Change: -0.97, Percent Change: -2.45","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0314104364.USD","BK4504","LU0158827948.USD","LU0098860793.USD","LU0320765646.SGD","LU2271345857.HKD","LU0912757837.SGD","LU0795875169.SGD","LU1989772840.SGD","LU2133065610.SGD","LU1732799900.SGD","IE00BZ1G4Q59.USD","BK4516","BK4183","LU1791710400.SGD","LU0882574139.USD","LU0158827781.USD","LU0971096721.USD","BK4585","LU2089283258.USD","LU0267386448.USD","IE0009354923.USD","BK4581","LU1162221912.USD","LU1720051017.SGD","LU2089284900.SGD","LU0557290698.USD","LU1989772923.USD","LU0006306889.USD","LU0106261372.USD","BK4534","IE00BKVL7J92.USD","ODD","LU0106831901.USD","LU0234570918.USD","LU0528227936.USD","LU1244550577.SGD","LU1732800096.USD","LU2023251221.USD","LU1244550221.USD","LU1791710582.SGD","BK4127","LU1720051108.HKD","LU2357305700.SGD","LU2111349929.HKD","LU1548497426.USD","LU1363072403.SGD","LU0795875086.SGD","LU0225283273.USD","LU2028103732.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://oddity.com","stockEarnings":[{"period":"1week","weight":-0.0006},{"period":"1month","weight":-0.1494},{"period":"3month","weight":-0.3038},{"period":"6month","weight":-0.4915},{"period":"1year","weight":-0.1925},{"period":"ytd","weight":-0.119}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oddity Tech Ltd. operates as a consumer tech company that builds and scales digital-first brands to disrupt beauty and wellness industries. The company serves consumers worldwide through its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. It owns IL MAKIAGE and SpoiledChild brands. The company was incorporated in 2013 and is headquartered in Tel Aviv, Israel with additional office in New York, New York.","exchange":"NASDAQ","name":"ODDITY Tech Ltd.","nameEN":"ODDITY Tech Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ODDITY Tech Ltd.(ODD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ODDITY Tech Ltd.,ODD,ODDITY Tech Ltd.股票,ODDITY Tech Ltd.股票老虎,ODDITY Tech Ltd.股票老虎国际,ODDITY Tech Ltd.行情,ODDITY Tech Ltd.股票行情,ODDITY Tech Ltd.股价,ODDITY Tech Ltd.股市,ODDITY Tech Ltd.股票价格,ODDITY Tech Ltd.股票交易,ODDITY Tech Ltd.股票购买,ODDITY Tech Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ODDITY Tech Ltd.(ODD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}